BRPI0609809A2 - polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado - Google Patents

polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado Download PDF

Info

Publication number
BRPI0609809A2
BRPI0609809A2 BRPI0609809-6A BRPI0609809A BRPI0609809A2 BR PI0609809 A2 BRPI0609809 A2 BR PI0609809A2 BR PI0609809 A BRPI0609809 A BR PI0609809A BR PI0609809 A2 BRPI0609809 A2 BR PI0609809A2
Authority
BR
Brazil
Prior art keywords
seq
polypeptide
sequence
amino acid
virus
Prior art date
Application number
BRPI0609809-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Madan M Paidhungat
Ian Sas
Thomas Bouquin
David Lin
Teddy Chen
Douglas Guptill
Amy Brideau-Andersen
Steven H Bass
Phillip A Patten
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of BRPI0609809A2 publication Critical patent/BRPI0609809A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0609809-6A 2005-05-18 2006-05-17 polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado BRPI0609809A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68276905P 2005-05-18 2005-05-18
US60/682769 2005-05-18
PCT/US2006/019088 WO2007044083A2 (en) 2005-05-18 2006-05-17 Evolved interferon-alpha polypeptides

Publications (1)

Publication Number Publication Date
BRPI0609809A2 true BRPI0609809A2 (pt) 2011-10-11

Family

ID=37943260

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0609809-6A BRPI0609809A2 (pt) 2005-05-18 2006-05-17 polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado

Country Status (11)

Country Link
US (1) US7619067B2 (enExample)
EP (1) EP1888633A4 (enExample)
JP (1) JP2008545393A (enExample)
KR (1) KR20080019619A (enExample)
CN (1) CN101501068A (enExample)
AU (1) AU2006299901A1 (enExample)
BR (1) BRPI0609809A2 (enExample)
CA (1) CA2607651A1 (enExample)
IL (1) IL186880A0 (enExample)
MX (1) MX2007014524A (enExample)
WO (1) WO2007044083A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040715A2 (en) 1999-01-05 2000-07-13 Trustees Of Boston University Improved nucleic acid cloning
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
JP2008519602A (ja) 2004-11-11 2008-06-12 モジュラー ジェネティクス， インコーポレイテッド 多様性を生じるためのラダーアセンブリおよびシステム
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009030066A1 (en) * 2007-09-04 2009-03-12 Biosteed Gene Expression Tech. Co., Ltd. Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
US9005599B2 (en) 2008-04-21 2015-04-14 Tissue Regeneration Therapeutics Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
CN101921330B (zh) * 2010-06-02 2013-07-17 北京三元基因工程有限公司 重组人干扰素α1b突变体及其制备方法
EP3799880A3 (en) 2012-03-03 2021-06-23 ImmunGene, Inc. Engineered antibody-interferon mutant fusion molecules
EP3349783B1 (en) * 2015-09-15 2024-01-17 ILC Therapeutics Ltd Compositions and methods relating to the treatment of diseases
CN108733975B (zh) * 2018-03-29 2021-09-07 深圳裕策生物科技有限公司 基于二代测序的肿瘤克隆变异检测方法、装置和存储介质
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
CN114891088B (zh) * 2019-06-13 2023-07-25 江苏科技大学 鸭α干扰素及其突变体、制备方法和应用
PL4121092T3 (pl) * 2020-03-16 2024-08-19 Ilc Therapeutics Ltd Hybrydowe interferony do leczenia zakażeń wirusowych
EP3901168A1 (en) * 2020-04-21 2021-10-27 Universität Duisburg-Essen Interferon alpha 2 variants and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
EP0098876A1 (en) 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
JP3496937B2 (ja) 1990-10-17 2004-02-16 アムジエン・インコーポレーテツド コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
DK0741577T3 (da) 1994-03-07 2003-02-17 Imperial College Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
NZ513077A (en) 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
AU3725600A (en) 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
CN1361793A (zh) 1999-05-19 2002-07-31 利思进药品公司 干扰素－α蛋白作为Fc融合蛋白的表达和运输
CA2385045A1 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
DE60307881T2 (de) * 2002-11-15 2007-03-08 F. Hoffmann-La Roche Ag Positionelle isomeren von pegyliertem interferon alpha 2a
AU2003297285A1 (en) * 2002-11-18 2004-06-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BRPI0511196A (pt) 2004-05-19 2007-12-04 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição

Also Published As

Publication number Publication date
CA2607651A1 (en) 2007-04-19
WO2007044083A2 (en) 2007-04-19
KR20080019619A (ko) 2008-03-04
MX2007014524A (es) 2008-02-07
EP1888633A2 (en) 2008-02-20
US7619067B2 (en) 2009-11-17
IL186880A0 (en) 2008-02-09
AU2006299901A1 (en) 2007-04-19
EP1888633A4 (en) 2010-01-27
CN101501068A (zh) 2009-08-05
WO2007044083A3 (en) 2009-04-16
US20080226597A1 (en) 2008-09-18
JP2008545393A (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
US7541163B2 (en) Interferon-alpha polypeptides and conjugates
US7314613B2 (en) Interferon-alpha polypeptides and conjugates
BRPI0609809A2 (pt) polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
MXPA05005263A (es) Polipeptidos y conjugados de interferon alfa.
KR20070022279A (ko) 인터페론-알파 폴리펩티드 및 컨쥬게이트

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]